Notice for loncastuximab tesirine (Swedish Orphan Biovitrum Pty Ltd)
Active ingredients
loncastuximab tesirine
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Powder for concentrate for solution for infusion
Indication
Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
Therapeutic area
Oncology